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Letters to the Editor
Authors’ response:
We thank Ms. Pickett for her interest in ‘‘The
American Journal of Cardiology and Journal of
Periodontology Editors’ Consensus: Periodontitis
and Atherosclerotic Cardiovascular Disease’’ and
her thoughtful comments, and we appreciate the
opportunity to clarify some of the confusion regarding
the aim of the document and the evidence. The
consensus report attempted to translate what is
currently known about the relationship between these
two diseases into practical application, while recog-
nizing that recommendations are based on judgments
of potential risks and benefits given the current state
of knowledge.
Ms. Pickett concludes that there is no evidence that
atherosclerotic events can be prevented with peri-
odontal therapy, and therefore suggests that the rec-
ommendations cannot be supported. We concur with
Ms. Pickett that there is no current direct evidence that
atherosclerotic cardiovascular disease (CVD) events
can be prevented by treating periodontal disease, and
we repeatedly indicated the same in the document. To
emphasize this point, we placed the following state-
ment immediately before the recommendations:
‘‘Although the treatment of periodontitis reduces
systemic markers of inflammation and endothelial
dysfunction, no prospective periodontitis intervention
studies have evaluated CVD outcomes.’’ Thus, we
tried to make clear in the recommendations that
clinicians should not be treating periodontal disease
solely for the purpose of preventing CVD events.
However, there is growing evidence that periodontal
therapy can reduce traditional risk factors for cardio-
vascular events, for example, elevated C-reactive
protein and impaired endothelial function. Clinicians
are very interested in what these studies mean and
how they should apply the information.
Ms. Pickett also suggests that an added risk of 24%
to 35% reported in one systematic review and relative
risk ratios between 1.1 and 2.2 are very weak to
moderate associations. While this is true, periodontal
disease and heart disease are very prevalent in the
population, and an effect size that is weak to moderate
can affect a large number of lives. For example, in
2005, there were 864,000 deaths from cardiovas-
cular diseases in the United States, according to the
American Heart Association.1 These events occurred
in an at-risk adult population, over age 18, of 296
million individuals (2005 U.S. census data2). A 25%
increase in risk (i.e., a 1.25 odds ratio) would translate
into roughly 216,000 new lethal events for that
year. In our opinion, this is not a trivial health issue
for practicing periodontists, since CVD is the most
prevalent medical condition among our patients. We
should also note that the meta-analysis effect size of
the independent influence of periodontitis on athero-
sclerotic CVD events is in the same range as meta-
analysis effect sizes of other accepted factors in the
management of atherosclerotic CVD. For example, in
a recent review of meta-analyses3 on the benefits of
statins in reducing cardiovascular outcomes, effect
sizes of a 12% decrease in all-cause mortality and
a 19% decrease in coronary heart disease mortality
are reported.
As part of the support for a claim of inadequate
evidence, Ms. Pickett discusses a review of a recent
intervention study (Beck et al.4) ‘‘. . . that has ad-
dressed the outcome of periodontal intervention in
subjects with heart disease suggesting that peri-
odontal intervention may not induce more serious
adverse events than what might be expected in the
community over a 25 month period.’’5 She addition-
ally quotes: ‘‘Furthermore the study demonstrated
that non-surgical routine periodontal therapy did not
reduce the risk of serious cardiovascular events.’’5
For readers not familiar with the Beck et al. study,4 it
was a report on adverse events that occurred sub-
sequent to periodontal treatment consisting of scal-
ing, root planing, and oral hygiene instruction. It was
a pilot study, which means that it was not adequately
sized to result in a reliable estimate of the effect of
periodontal treatment on cardiovascular endpoints.
Thus, all the results reported in this study focused on
adverse events or serious adverse events (SAEs) to
determine whether providing periodontal therapy was
safe or whether it might be deleterious to patients with
established heart disease. There were only 15 SAEs in
the study, but 13 of the 15 involved some type of
cardiovascular event. The article clearly states:
‘‘Thus, cardiovascular SAEs do not meet all of the
standards for determining endpoints, and the trends
shown for SAEs should not be equated with what an
analysis of the effect of periodontal treatment on
cardiovascular endpoints might show.’’4 The stated
conclusion of the study was: ‘‘For those individuals
who remained in the study, it appears that provision of
periodontal scaling and root planing treatment to
individuals with heart disease resulted in a similar
pattern of adverse events as seen in the community
care group, which also received some treatment.’’4
Perhaps by further reconsidering these key points and
conclusions from this study, Ms. Pickett’s expressed
concerns may be resolved.
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Ms. Pickett further cites our reference to meta-
analyses which conclude that the associations require
further study and our qualification that ‘‘. . . peri-
odontitis may independently increase the risk for
CVD.’’ She concludes that she is confused as this
appears to be in contrast with our stated aim, which is
selectively presented in her letter. There are two
considerations that can clarify our position. First, we
state that the aim is contingent ‘‘on the basis of current
information’’; thus, our recommendations are quali-
fied and not intended to be definitive. Secondly, Ms.
Pickett states that ‘‘. . . the evidence-based science . . .
do[es] not appear to support that inference.’’ To this
point, we would emphasize that it is important to
appreciate that interventions may be demonstrated
to influence the impact of known risk factors on
the primary outcome before being demonstrated
to affect the primary outcomes, such as events in
cardiovascular disease. For example, as noted in
package inserts, many lipid-lowering agents cur-
rently approved by the U.S. Food and Drug Ad-
ministration have not been shown to reduce events.
Thus, the state of the science that we have outlined
relates to these risk modifications, and we have quali-
fied all statements to not imply a known effect on
outcomes.
Ms. Pickett also expressed concern that ‘‘. . . there
was not an adequate inclusion of negative studies . . . .’’
Although the report was not intended to be a system-
atic review of primary sources, conclusions from
published systematic reviews and meta-analyses
were included to represent the evidence supporting
the key statements that form the basis for recom-
mendations. We then tried to explicitly describe the
limitations of current evidence. For example, in
referring to the evidence for the association between
periodontitis and atherosclerotic CVD, we stated:
‘‘The findings of these studies, however, have varied
greatly, ranging from determinations of no causative
relationship between periodontitis and CVD to strong
causative connections between the two conditions.’’
We attempted to provide a balanced perspective on
the current state of knowledge in the field, but some
readers may feel that we were overly conservative in
our statements and others may feel that we did not go
far enough.
As noted in the original editorial6 accompanying
the publication of this consensus report, practitioners
are unsure how to apply the current evidence to
clinical practice. One of our goals for the report was to
clarify that current evidence does not support treat-
ment of periodontal disease to reduce CVD events.
However, this does not mean that periodontal therapy
does not have a beneficial effect on the cardiovascular
system. We think this is a step in the right direction,
based on the current evidence. Of course, the entire
premise underlying clinical guidelines and recom-
mendations is that expert judgments of risk and
benefit considerations may be used to guide clinical
applications of current knowledge prior to the avail-
ability of definitive clinical evidence. That is the basis
for clinical judgments that must be made daily in clin-
ical practice, while we are waiting for more definitive
evidence.
The process involved in developing clinical guide-
lines and clinical recommendations may have
confused Ms. Pickett and other readers, since recom-
mendations are often made in the absence of the
highest level of evidence. For example, in the past 10
years, there have been 33 clinical practice guidelines
issued jointly by the American College of Cardiology
and the American Heart Association. Of the 2,711
recommendations included in the 16 guidelines that
are current and report the level of evidence, 314
(11.5%) are based on a level of evidence of A (multiple
randomized trials or meta-analyses), while 1,246
(46%) have a level of evidence of C (expert opinions,
case studies, standards of care).7
One of the advantages of defining such clinical
recommendations, based on current assessments of
potential benefits and risks, is that it begins to focus
and define critical research and funding agendas. Ms.
Pickett urges investigation of the cost-effectiveness of
the recommendations, and that is certainly a worth-
while goal. Some data are starting to emerge to
support cost-effectiveness modeling relative to the
relationships among various diseases. For example,
a recent pilot study8 suggests that elevated HbA1c
levels may be found in >25% of patients with periodon-
titis and at a frequency twice that of dental patients
without periodontitis.
Ms. Pickett expresses concern about insufficient
evidence presented in the editors’ consensus report to
support the following statement made in the report:
‘‘Treatment of periodontal disease, especially in
patients with elevated glycosylated hemoglobin,
improves glycemic control.’’ Ms. Pickett observes
that the meta-analysis published by Darré et al.,9
cited as one of the two references to support the
statement in the consensus report, offers a more
reserved conclusion regarding the evidence synthe-
sized from their review in stating ‘‘. . . periodontal
treatment could improve glycaemic control’’ than is
stated in the consensus report. Ms. Pickett also
observes that the improvement in glycemic control
in the second reference cited in the consensus
report10 occurred only in participants receiving
periodontal treatment and doxycycline. Finally,
Ms. Pickett shares her belief that ‘‘. . . only positive
studies were referenced . . .’’ in the consensus report.
Based on these observations, Ms. Pickett suggests
that more appropriate wording for the statement in
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the consensus report should have been: ‘‘Treatment
of periodontal disease using various therapies plus
doxycycline . . . improves glycemic control for at
least 3 months.’’
Drs. George W. Taylor and Wenche S. Borgnakke
have recently reviewed the literature relative to the
effects of periodontal treatment on glycemic control,
including all of the articles reported in Darré et al.9
(report in press; Delta Dental Plans). The 11 random-
ized clinical trials (RCTs) on this topic used control
groups that were either non-treated controls, positive
controls (i.e., the control group received a relatively
less intense form of periodontal treatment), or con-
trols advised to continue their usual dental care. Of
the 11 RCTs reviewed by Taylor and Borgnakke,
seven reported a beneficial effect of periodontal
therapy on glycemic control. An important source of
variation in the RCTs’ characteristics was the use of
adjunctive antibiotics with the non-surgical periodon-
tal therapy. Among the seven RCTs that included
adjunctive antibiotics, five used the antibiotics sys-
temically10-14 and two used local delivery.15,16 The
antibiotics used in these studies included systemic
doxycycline, systemic amoxicillin and amoxicillin
clavulanate, and locally delivered minocycline. Six
of these seven RCTs using adjunctive antibiotics
showed beneficial effects on glycemic control.10,12-16
However, it is important to note the greatest improve-
ment for one study was in the positive control group
that did not receive the systemic antibiotic.13 Also,
one of the seven RCTs reporting a beneficial effect did
not use any antibiotics.17 Hence, to date, there is no
clear-cut evidence to support a requirement for the
use of antibiotics in combination with non-surgical
periodontal treatment in order to observe an improve-
ment in glycemic control associated with non-surgical
periodontal therapy. The use of adjunctive (local or
systemic) antibiotics remains controversial. Addi-
tional well-conducted studies would help to evaluate
adjunctive antibiotic effectiveness in terms of type,
route of administration, dose, and indication based
on level of glycemic control. Therefore, based
on systematic reviews and interpretation of the
literature, the authors of the ‘‘Editors’ Consensus:
Periodontitis and Atherosclerotic Cardiovascular
Disease’’ and colleagues consulted on this topic
believe the evidence is encouraging in support of
a beneficial effect of periodontal treatment on
glycemic control; however, the evidence is not yet
sufficiently firm to declare unequivocally that treat-
ment of periodontal disease improves glycemic
control. Our conclusion is consistent with the Darré
et al.9 conclusion. Ms. Pickett’s suggestion for
alternative wording in the consensus statement,
‘‘Treatment of periodontal disease using various
therapies plus doxycycline . . . improves glycemic
control for at least 3 months’’ would not adequately
reflect the evidence. The effectiveness of adjunctive
antibiotics in contributing to glycemic control has
not been established. Finally, Ms. Pickett’s belief
that ‘‘. . . only positive studies were referenced . . .’’ is
not entirely correct. The Darré et al.9 meta-analysis
included several studies showing a non-significant
beneficial effect as well as one study that showed
a non-significant worsening of glycemic control
following periodontal therapy. We believe the col-
lection of articles in the Darré et al. reference
adequately represented the body of literature on this
topic at the time it was published. As the focus of the
consensus report was on CVD, using the Darré et al.
reference was an efficient way to reasonably present
the body of evidence to the reader.
Finally, Ms. Pickett implies that there is an inherent
problem with educational grants from industry and
with the authors’ disclosed financial relationships.
The Journal of Periodontology practices a policy of
full disclosure of funding sources and financial re-
lationships of authors, in order that readers may make
informed decisions on the potential for conflicting
interests. As is common practice today, we seek to
manage and balance potential conflicts, rather than
eliminate all participants who may have a potential
conflict. The disclosed educational grant to the
American Academy of Periodontology (AAP) was
handled as is typical of such grants – i.e., the sponsor
had absolutely no role in the planning, selection of
participants, conduct of the conference, or drafting or
review of the report. All expenses and faculty stipends
were provided by the AAP.
CONCLUSIONS
Some clinical research findings, if validated, may
have substantial health implications. In recent years,
clinical practice recommendations have been
developed in many areas based on the potential
to derive health benefits by translating the research
into clinical practice immediately. Such recommen-
dations rarely have the benefit of perfect knowledge
and overwhelming benefits but usually represent
judgments on the relative benefits and risks based
on confidence in the current evidence. Although
not perfect, such judgments can lead to clinically
useful information and have the potential to produce
health benefits while we wait for more definitive
evidence.
Vincent E. Friedewald, Associate Editor, The American
Journal of Cardiology; Kenneth S. Kornman, Editor-
in-Chief, Journal of Periodontology; Steven Offen-
bacher and James Beck, University of North Carolina,
Chapel Hill, NC; and George W. Taylor and Wenche S.
Borgnakke, University of Michigan, Ann Arbor, MI.
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